Plasma folate level and high-dose folate supplementation predict sulfadoxine-pyrimethamine treatment failure in pregnant women in Western kenya who have uncomplicated malaria.
Level II
Where this comes from
- Record sourced from PubMed, PMID 18831691.
- Also identified by DOI 10.1086/592715.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sulfadoxine-pyrimethamine (SP) inhibits folate metabolism by the malaria parasite. We investigated the association between folate levels and SP failure in pregnant women. Data from a trial to assess the effect that folate supplementation has on SP failure in 467 pregnant women were analyzed. Plasma folate levels were determined at enrollment and at day 7. High baseline folate levels, high parasite densities, and age <20 years were risk factors for SP failure. High-dose (5 mg daily) folate supplementation or high folate levels at day 7 were independent risk factors. Therefore, pregnant women receiving SP should receive low-/moderate-dose folate supplementation. http://www.clinicaltrials.gov identifier: NCT00130065.
Medical subject headings
- Antimalarials
- Dietary Supplements
- Folic Acid
- Malaria
- Pregnancy Complications, Parasitic
- Pyrimethamine
- Sulfadoxine